Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1215968 | 0.87 | MAP2K1 (0.38) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1216151 | 0.87 | MAP2K1 (0.44) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1217348 | 0.87 | MAP2K1 (0.47) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1219052 | 0.82 | MAP2K1 (0.51) | MAP2K1MAP2K2 | |
| SCHEMBL1921009 | 0.80 | MAPT (0.42) | KDM4EALDH1A1HPGDGAATSHR | |
| SCHEMBL2564946 | 0.80 | MAP2K1 (0.51) | KDM4EALDH1A1HPGDGAATSHR | |
| SCHEMBL1216500 | 0.79 | MAP2K1 (0.44) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1218574 | 0.79 | MAP2K1 (0.47) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1218952 | 0.79 | MAP2K1 (0.41) | MAP2K1MAP2K2 | |
| SCHEMBL4981994 | 0.76 | MAP2K1 (0.51) | KDM4EALDH1A1GAALMNABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069359-B1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2069359-B1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-7893085-B2 | 3-(4-Bromo-2-fluoro-phenylamino)-thieno[3,2-c]pyridine-2-carboxylic acid (2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide; mitogen activated protein extracellular kinase kinase (MEK) inhibitor; antiproliferative, antiinflammatory agent | GENENTECH, INC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893085-B2 | 3-(4-Bromo-2-fluoro-phenylamino)-thieno[3,2-c]pyridine-2-carboxylic acid (2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide; mitogen activated protein extracellular kinase kinase (MEK) inhibitor; antiproliferative, antiinflammatory agent | GENENTECH, INC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893085-B2 | 3-(4-Bromo-2-fluoro-phenylamino)-thieno[3,2-c]pyridine-2-carboxylic acid (2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide; mitogen activated protein extracellular kinase kinase (MEK) inhibitor; antiproliferative, antiinflammatory agent | GENENTECH, INC (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2069359-A1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| WO-2008024724-A1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | MKI67, CDKN1A, MAP3K1 | KDM4E 190/4885ALDH1A1 1154/4885HPGD 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.